Haryana FDA Busts Spurious Medicine Factory At Barwala

Panchkula : The Haryana Food and Drug Administration (FDA) busted a spurious medicine factory in Barwala, Panchkula, here on Friday. The factory allegedly used to supply spurious medicines from Barwala to Delhi. It is suspected to be a big racket of counterfeit medicines at national level.

As per the information shared by an FDA spokesperson, the officials of the department had earlier received complaints that counterfeit products of a medicine factory, Relieve Pharmaceuticals of Chandpur, Una, Himachal Pradesh, are being made and sold, from the owner Sukesh Chandra.

Acting on the information, a team was constituted under the leadership of FDA’s Assistant State Drug Controller Ripon Mehta, along with Senior Drug Control Officer, Ambala, Sunil Dahiya and drug control officer, Panchkula.

The team raided Cubic Light Science Private Limited, located at Industrial Area, Barwala, Panchkula, during which the team found 320 mg and 100 mg tablets which were branded as K2 tablets and with active ingredients calcium citrate, vitamin K-27, zinc and magnesium. The cost of these medicines has been estimated at Rs 5,69,940.

The manufacturer’s name printed on these counterfeit medicines was of Relieve Pharmaceuticals. The fake consignment of counterfeit medicines is said to have come from Bawana, Delhi. Sukesh Chandra informed the FDA team that they do not have any factory or office in Barwala or Delhi.

The team collected the sample of the medicines from the spot for testing and has seized the rest of the goods in its possession for further legal action. No police complaint has been registered yet and no arrests have been made in the matter.

The Delhi Drugs Department has been informed so that the racket can be busted. In the last few days, this is the fifth factory found making fake medicines.

  • Related Posts

    India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

    The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

    India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

    Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

    India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

    India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

    India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

    India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

    India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

    Novo Nordisk gears up for December Ozempic launch

    Novo Nordisk gears up for December Ozempic launch

    Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

    Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

    Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

    Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit